Crossmark

Neoadjuvant chemoradiotherapy plus sintilimab in proficient mismatch repair locally advanced rectal cancer with intermediate/high-immunoscore (SILAR): a single-arm phase II trial

Crossref DOI link: https://doi.org/10.1038/s41467-025-65162-8

Published Online: 2026-01-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zheng, Xiaobin https://orcid.org/0000-0001-9748-6411
Liu, Huashan https://orcid.org/0000-0002-8932-4866
Shi, Lishuo

Zeng, Ziwei https://orcid.org/0000-0001-8789-821X
Zhang, Xingwei

Luo, Shuangling

Cai, Yonghua

Li, Ze

Liu, Zhanzhen

Hou, Yujie

Yang, Zuli

He, Xiaowen

Ke, Jia

Huang, Liang

Luo, Yanxin https://orcid.org/0000-0002-5200-3997
Kang, Liang https://orcid.org/0000-0001-7062-8280
License Information

Text and Data Mining valid from 2026-01-21

Version of Record valid from 2026-01-21
More Information

Article History

Received: 25 November 2024

Accepted: 8 October 2025

First Online: 21 January 2026

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below